Please login to the form below

Not currently logged in
Email:
Password:

checkpoint inhibitor

This page shows the latest checkpoint inhibitor news and features for those working in and with pharma, biotech and healthcare.

Opdivo improves survival in oesophageal cancer

Opdivo improves survival in oesophageal cancer

BMS releases new data from its phase 3 CHECKMATE-648 study. In interim results released yesterday, Bristol Myers Squibb's (BMS) Opdivo, a PD-(L) 1 checkpoint inhibitor showed improved survival ... These results for BMS’ PD-(L) 1 checkpoint inhibitor

Latest news

More from news
Approximately 9 fully matching, plus 209 partially matching documents found.

Latest Intelligence

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    Immune checkpoint inhibitors. Immune (T) cells exhibit proteins that can turn an immune response on or off, called checkpoint proteins. ... Several checkpoint inhibitor drugs have been developed showing strong event- free survival and PFS rates, opening

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    These compounds could be used to tackle resistance to kinase inhibitor drugs, for example. ... The lead project in that partnership is an inhibitor of CBL-B, an immune checkpoint that is still in preclinical development and will migrate to Bristol-Myers

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    checkpoint inhibitor Imfinzi such as the POSEIDON trial in first-line NSCLC, are key newsflow events this year. ... Trial results for Opdivo alongside CTLA4 checkpoint inhibitor Yervoy (ipilimumab) are one key element of that, particularly better

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... 50%. The true figure for patients treated with checkpoint inhibitor monotherapy achieving durable and meaningful clinical responses is in fact nearer 20%.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Merck/MSD looks to have gained a dominant position in checkpoint inhibitor immuno-oncology (IO) with Keytruda – but there remains room for growth in the market via new IO agents. ... t the only oral JAK inhibitor developer with its eye on that

More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics